Astellas Pharma Inc., The Current Fiscal Year Net Income Revised Upward by 67%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Wed Oct 30, 2024 3:00 pm JST Earnings

4503 Astellas Pharma Inc. 【IFRS】

Earnings Report

Astellas Pharma Inc. <4503> [TSE-P] announced its financial results (based on IFRS) after the market closed on October 30th (15:00). The consolidated net income for the cumulative second quarter of the fiscal year ending March 2025 (April to September) surged by 2.1 times that of the same period last year, reaching 73.5 billion yen.

In addition, the full-year consolidated net income has been revised upward by 66.7%, from the previous forecast of 30 billion yen to 50 billion yen (compared to 17 billion yen in the previous period), increasing the growth rate from 76.0% to 2.9 times.

Based on the first-half performance announced by the company and the full-year plan, our calculation indicates that the consolidated net loss for the October to March period (second half) is expected to expand to a loss of 23.5 billion yen (compared to a loss of 18.7 billion yen in the same period last year).

In the most recent three-month period, from July to September (2Q), the consolidated net income surged to 13 times that of the same period last year, reaching 35.9 billion yen. The operating profit margin drastically improved from 2.4% in the same period last year to 9.3%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Sep, 2022	762,185	119,891	120,480	96,434	52.9	91.0	Oct 31, 2022	IFRS
Apr - Sep, 2023	767,138	55,156	56,318	35,810	20.0	225.6	Nov 1, 2023	IFRS
Apr - Sep, 2024	935,621	93,710	89,042	73,511	41.1	127.2	Oct 30, 2024	IFRS
YoY	+22.0%	+69.9%	+58.1%	+105.3%	+105.6%

First Half Results vs. Previous Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Apr - Sep, 2024 Guidance	ー	ー	ー	ー	－	37	Apr 25, 2024	IFRS
Apr - Sep, 2024 Results	935,621	93,710	89,042	73,511	41.1	37	Oct 30, 2024	IFRS
Revision Rate	－	－	－	－	－

Guidance Update

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	1,650,000	48,000	43,000	30,000	16.8	74	Apr 25, 2024	IFRS
Mar, 2025 New	1,800,000	80,000	70,000	50,000	27.9	74	Oct 30, 2024	IFRS
Revision Rate	+9.1%	+66.7%	+62.8%	+66.7%	+66.6%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	836,534	-29,638	-31,349	-18,765	-10.5	35	Apr 25, 2024	IFRS
Oct - Mar, 2024 Guidance	864,379	-13,710	-19,042	-23,511	-13.1	37	Oct 30, 2024	IFRS
YoY	+3.3%	+53.7%	+39.3%	-25.3%	-25.4%

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	1,518,619	133,029	132,361	98,714	54.2	60	Apr 27, 2023	IFRS
Mar, 2024	1,603,672	25,518	24,969	17,045	9.5	70	Apr 25, 2024	IFRS
Mar, 2025 Guidance	1,800,000	80,000	70,000	50,000	27.9	74	Oct 30, 2024	IFRS
YoY	+12.2%	+213.5%	+180.3%	+193.3%	+193.7%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jul - Sep, 2023	392,148	9,362	9,468	2,681	1.5	2.4	Nov 1, 2023	IFRS
Oct - Dec, 2023	421,932	18,963	17,312	14,513	8.1	4.5	Feb 5, 2024	IFRS
Jan - Mar, 2024	414,602	-48,601	-48,661	-33,278	-18.6	-11.7	Apr 25, 2024	IFRS
Apr - Jun, 2024	473,124	50,657	50,495	37,603	21.0	10.7	Aug 1, 2024	IFRS
Jul - Sep, 2024	462,497	43,053	38,547	35,908	20.1	9.3	Oct 30, 2024	IFRS
YoY	+17.9%	+359.9%	+307.1%	+1,239.4%	+1,237.3%